||EPS - Basic
||Market Cap (m)
Real-Time news about Mdy Healthcare (London Stock Exchange): 0 recent articles
|heaven: Why if they are paying 52p back to shareholders on the register 30th March 2012, is the share price at 50p + today? What is to stop you selling today and still receive the return of capital?|
|aberdeen_angus: DY Healthcare SPECULATIVE BUY
09/11/2011 Miles Nolan
With public information, how do you turn an investment of 50p a share into a potential return of 40%? Take a look at AIM listed MDY Healthcare for more information.
For those of you with long memories, this was the old syringe developer Medisys. Over several years it spent millions on 'product development' but returned little to shareholders - other than a slump in the share price. Wind the clock on and MDY Healthcare is now in a position to provide a useful return.
Aided by new management, including ex-banker Grahame Cook and medtech specialist Martin Hunt, the business is now worthy of closer attention. Last month it unveiled the disposal of Medivance, one of its two remaining healthcare investments.
US giant C.R.Bard is paying $250m for the temperature management specialist - which equates to up to £13.125m for MDY, or more interestingly 73 to 77p a share. Costs have been cut and there are debts in MDY of £1.65m, but there also remains a 14.5% stake in AIM hopeful Stanmore (an orthopaedic business).
Q. Does anybody know the current valuation of the MDY investment in Stanmore?|
|jimmyloser: 15/11/2011 Miles Nolan
The recent £43.8 million acquisition of AIM-listed catheter-to-stent manufacturer Clearstream by US giant C.R. Bard has provided shareholders with a decent exit. So who could be next?
Every day I sift through streams of RNS announcements, but last month one in particular caught my eye. Shares in healthcare investor MDY Healthcare almost quadrupled in value, on the news that it was to realise its investment in Medivance.
None other than C.R. Bard has agreed to pay $250 million for the Colorado-based leader in the emerging field of therapeutic temperature management. Its patented, FDA-approved Arctic Sun device helps deliver precise control over core body temperature after traumatic medical events. Thanks to strong demand for its products, it has enjoyed growth in 27 out of the past 29 quarters.
MDY has invested a total of $6 million (most recently $1 million in June 2009) for its 10.4 per cent holding. This, when completion takes places in the final quarter of 2011, will result in a payment of £12.5 million to £13.125 million.
For MDY, this equates to a windfall of 73p to 77p a share not bad when compared with its lowly share price of 41p, which values the AIM counter at bang on £7 million.
MDY has total debts of £1.65 million, so even after being repaid it should leave a tidy profit. Management is to set out a strategy for the use of the proceeds, but this is not the end of the story.
MDY also has one other investment a 14.5 per cent stake in Stanmore. Founded in 1949, this is an orthopaedic business focused on saving and restoring the function of limbs and joints.
It was a UCL spin-out, and is on track to deliver sales of £7.5 million this year, fuelled by distribution to 15 countries.
MDY has completed a planned cost reduction exercise, which includes assigning its onerous office lease. In my opinion, the shares have further to run|
|dyfiman: FOR JIMMY
There's gold in them there pills says MDY Healthcare Oct 26, 2011
friends:inShare.0Email..Comments (0) Print this article
Investment firm MDY Healthcare has seen its share price more than triple after announcing an impressive profit on a deal in the US.
MDY is selling its 10.4% stake in Medivance for around $20m. This return is on a total investment of $6m plus sterling debts of £1.65m
In other words MDY has made an absolute killing.
It now only has one remaining investment, in another medical firm called Stanmore.
MDY says it will now ponder what to do with its roughly $14m war chest.
Shares in the firm now stand at 46p up from 12.5p, a rise of 268%. Not a bad day at the office then.
Since he left MDY, the share price crashed from 30p to 13p. Looks like the new management has excelled itself!
By the way, Wong's Chinese medical training outfit CERT, has a made a donation to Oxford University to create a new medical emergency unit and the amount is more that MDY's currentmarket cap! So he must be doing quite well unlike MDY.
And yes, MDY's board ex Wong, rejected the proposal to invest in CERT.
monte1 - 1 Jul'11 - 13:13 - 3709 of 3709
He has gone to maximise* shareholder value in another AIM POS - GON.
|jenniferzz: Bluebelle/Yaki? anyone else remotely interested.
1 I find it a bit of a puzzle that you post the headlines of the broker note that oozes positive about this other stock you mention and yet when you are asked for more details, a natural question from an enquiring mind (Yaki) you say it would not be right to post it as came to you under a NDA. However, you post the positives about the stock for the whole world to see on the net. Not much of a secret there eh?
2 As an observation this reminds me of something that is a constant in the stock market the publication of notes which are of course just opinions that can lead to a tick up in price either through interest/news or because demand has been attracted in. Thus the price is moved up on the news and as they always say SELL the news and don't be part of the NEWS that assists others in selling the news.
3 The comment that you 'don't get many brokers notes that have a target of over x6 the current share price' is interesting. It is ironic that on the MDY thread you read that. When MDY was in the 30p region a broker note was issued by Nomura with a target price of over 350p, over x11 !! and we all know that the fairy tale story turned into a nightmare. (and before you say it did go there, yes it did after a share price consolidation and then a number of new share issues)
4 Having said all that, I take all notes with a pinch of salt, and I take snippets of the like from Bluebelle or any other BB poster with a great deal of caution. There is however a chance that some of it might be right and you might get a return on your investment, with of course the issue that you may well not! That is where stop losses come in. I know you don't use them much when it comes to MDY because you fear missing out on the upsurge that is sure to come but very rarely does or you feel you don't want to be wrong/lose your money which in reality you have!
5 All things considered in a desperate situation like MDY a switch completely out of MDY into another 'promised land' offers you more hope than MDY does.
6 But then again, take whatever I say with caution as you don't know me, who I am or if I have an agenda.
Be careful out there|
|dinky rinky: Down again to 22p bid !!
I think the MDY share price could do with a bit of quantitative easing.
|jenniferzz: As warned before it happend MDY would say in their results statement
'challenging market conditions'
This is said every year but I was caught out this year as they have upgraded their statement to:
'extremely challenging conditions'
This lends me to predict without any doubt a revision of my 20p soooooon to a conservative estimate that the stock will be between 10p to 15p this time next year with the possibility of extreme disaster not far away and the stock being worth 0p to 2p. Nice work eh ? a cull on costs reduced spend to a mere 1.4 million a year! for what !!!
Yours in my own opinion, ace deadhead, MDY critic and proven MDY share price forecaster. Cut and past this post in a years time adoring fans of MDY.|
|fletcher: I can believe this tread is still going.
There again I can believe this company is still going..
I wonder if anyone here has noticed a persistent trend that the MDY share price follows.|
|jenniferzz: Markinthe park
Sensible post about trading volume. It made sense to me and I thought it worthy of further comment. The target audience once again has failed to see the fundamental dynamics that relate to the MDY share price and the predictabe future direction of the share price.
Oh and Dinky, nice one|
MDY Healthcare share price data is direct from the London Stock Exchange